INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to…
INmune Bio (NASDAQ: INMB), a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease,…
INmune Bio (NASDAQ: INMB), focused on developing treatments that target the innate immune system to fight disease, was recently highlighted…
INmune Bio (NASDAQ: INMB), a biotechnology company focused on modulating components of the innate immune system to treat cancers and…
INmune Bio (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, on…
INmune Bio (NASDAQ: INMB) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report…
INmune Bio (NASDAQ: INMB) on Monday announced that Malú Tansey, Ph.D., Professor of Neuroscience and Director of the Center for…
INmune Bio, Inc. (NASDAQ: INMB) today announced a poster presentation related to its program in Alzheimer’s disease at the upcoming…
INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to…
RJ Tesi, M.D., co-founder and CEO of clinical-stage immunology company INmune Bio (NASDAQ: INMB), was recently featured in an interview…